BUSINESS
Budget 2023: Pharma gets a boost, Rs 1,250 crore set aside for bulk drug, medical device parks
Last year, the Centre had allocated only Rs 100 crore for the development of the pharma industry
BUSINESS
Budget 2023-24: Ayushman Bharat allocated Rs 7,200 crore
Budget 2023-24: The allocation for Ayushman Bharat, the world’s largest government-funded health assurance scheme, is 12 percent higher than Rs 6,412 crore allotted in FY23
TRENDS
Budget 2023: FM Sitharaman unveils new programme to promote innovation in pharma
The government will also encourage the pharma industry to invest in research and development in specific priority areas
TRENDS
Taslima Nasreen consented for hip replacement surgery: Apollo Hospitals on forced surgery claim by author
In a series of tweets, the exiled author blamed Apollo hospitals for botched hip replacement, alleging that the treating doctor advised her hip replacement surgery, while she complained of pain in knee.
TRENDS
Sun Pharma acquires 3 brands to strengthen anti-inflammatory portfolio
Acquired from Aksigen Hospital, Disperzyme, Disperzyme-CD and Phlogam have been approved by the Drugs Controller General of India for post-operative inflammation in patients undergoing minor surgery and dental procedures
BUSINESS
India Budget 2023: Pharma industry urges govt to focus on schemes for innovation, provide tax incentives on R&D
The industry leaders have pitched for re-evaluating India’s role in the global pharmaceuticals sector with innovation and technology as cornerstone.
TRENDS
Union Minister Chandrasekhar says Pfizer tried to bully government into giving indemnity to supply COVID jab
Pfizer had sought an emergency use authorisation for its jab in December 2020 but withdrew the proposal in February 2021 after failing to meet the drug regulator’s demand for a local safety study
TRENDS
Dr Reddy's completes clinical studies of key biosimilar, step closer to launching in US, Europe
The company will collaborate with partner Fresenius Kabi to commercialise the proposed biosimilar for treating illnesses such as arthritis and non-Hodgkin's lymphoma in the US but plans to take the product directly to EU and other regions
BUSINESS
Maiden Pharma’s cough syrups from Himachal plant flagged for adulteration
The syrups were found to be ‘not of standard quality’. The WHO had previously issued a medical alert for four cough syrups manufactured from the company’s Sonipat plant in Haryana
TRENDS
No evidence of deaths due to our cough syrup, attempt to tarnish India’s image: Marion Biotech
Noida-based firm puts up a strong defence in a letter to central and state drug authorities. Company says it followed British Pharmacopoeia standards while manufacturing two controversial syrups. It also questions the methodology used to find the cause of children’s deaths in Samarkand city of Uzbekistan.
TRENDS
Study linking bivalent vaccines with stroke: Govt says no signals of concern seen in India
Last week, the CDC and US FDA had said that Pfizer and BioNTech's updated (bivalent) COVID-19 vaccines could be linked to a type of brain (ischemic) stroke in people aged 65 and older
HEALTH
Killer Cough Syrup: Marion Biotech used untested ingredients procured from unapproved vendors
The firm had not even tested the ingredient properly for the presence of the contaminants diethylene glycol and ethylene glycol, before using it to manufacture the cough syrups.
TRENDS
Fresh inspection of Marion Biotech plant on after WHO flags 2 cough syrups
The inspection was ordered after WHO issued ‘medical product alert’ for cough syrups, including the one that was linked to the death of 18 children in Uzbekistan
TRENDS
WHO issues alert for 'substandard' Marion Biotech drugs linked to Uzbekistan tragedy
This is the second drug alert issued by WHO in a span of three months to Indian pharma company for manufacturing alleged contaminated cough syrup.
TRENDS
Budget 2023: Medtech sector hopes for increased R&D allocation, enhanced testing facilities to boost exports
In the Budget 2023, the industry expects Finance Minister Nirmala Sitharaman to allocate funds for advanced medical testing facilities pending completion
BUSINESS
Adulteration concerns: US FDA warning letter to Sun Pharma questions manufacturing practices at Halol facility
Violations include not cleaning equipment used to manufacture drugs and failing to prevent contamination, leading to adulteration, the FDA said. The US regulator has asked the firm to immediately assess global manufacturing operations to ensure its products conform to standards.
TRENDS
Uzbekistan cough syrup row: UP suspends manufacturing license of drug maker Marion Biotech
Marion Biotech had its manufacturing licence suspended after failing to respond to a show-cause notice by the regulatory authority.
TRENDS
Cough syrup test report awaited; Marion Biotech gets breather to respond on GMP violations
The Noida-based firm was given seven days to reply on manufacturing practice violations at its plant, but with a drug sample report awaited, the drug regulator has given additional time to the company to respond to the notice.
TRENDS
Serum Institute to start free COVID vaccine supply to government, other manufacturers await order
The government has sent a consignment list for supplying 80 lakh doses of Covishield to different consignees to Serum Institute of India, which will start the supply soon, an official said.
TRENDS
Drug contamination reports hurt Indian pharma, government must find a way: Experts
Reports about contaminated exported drugs have shaken peoples’ faith in medicines sold in India as well, impacting the sector’s domestic and international prospects.
INDIA
Uzbekistan Cough Syrup Deaths: Pharmexcil suspends membership of Marion Biotech
The suspension means that the company's exports will become ineligible for incentives under the Market Access Initiative Scheme.
TRENDS
Uzbekistan cough syrup row: Marion Biotech asked to completely halt drug production at Noida plant
According to the officials involved in the inspection of plants at Noida, a deviation from Schedule M for Good Manufacturing Practices was observed at Marion's plant and the regulators have asked to stop the total production at this unit.
TRENDS
Exclusive | Uzbek Cough Syrup row: Drug regulators inspect Marion Biotech's manufacturing site
Sources said that government officials inspected the manufacturing facility till late night and collected the Doc 1-Max cough syrup from the plant. Hasan Raza, Marion Biotech Pharma Company legal head also mentioned that the product has been halted.
BUSINESS
Uzbekistan claims cough syrup made in Noida responsible for death of 18 kids; CDSCO calls for causality assessment report
“We have taken note of the matter and have asked for the causality assessment report of the death of children from the authorities of Uzbekistan,” a top CDSCO official told Moneycontrol.
